Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36718044/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The open-label study program for calcitonin gene-related peptide-targeted migraine preventives confirms the favorable safety and efficacy profile of these drugs over time. Treatment adherence appears higher than with previous unspecific migraine preventives. Real-world data and post-marketing surveillance studies may corroborate and...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC2yrThis is a good review.
New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36759320/
New prophylactic drugs that target the CGRP pathway are promising treatment options for patients with difficult-to-treat migraine. Individualized approaches using a combination of new substances with oral prophylactic drugs or...
Conclusions: New prophylactic drugs that target the CGRP pathway are promising treatment options for patients with difficult-to-treat migraine. Individualized approaches using a combination of new substances with oral prophylactic drugs or botulinum toxin A, switching between new drugs, and adjusting treatment duration could enhance excellence...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC2yrThis is really needed.
Effectiveness and safety of CGRP monoclonal antibodies in migraine related to mitochondrial diseases in patients with NARP and PEO syndromes
Source : https://www.sciencedirect.com/science/article/abs/pii/S0303846723000276?via=ihub
Migraine or migraine-like headaches are a prominent feature of mitochondrial disorders (MD) with a prevalence ranging from 29% to 58% independently from diseases' genotypes or phenotypes, expression of the central...
Conclusions: Herein, we report the cases of a patient with neuropathy, ataxia, and retinitis pigmentosa syndrome (NARP) and a patient with progressive external ophthalmoplegia (PEO), both with a clinical phenotype including chronic migraine, for which treatment with Galcanezumab was started.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC2yrMay be a good expansion of use.
Psychological Resilience & Stress Coping Styles in Migraines | NDT
Stress is the most commonly known factor that triggers migraine pain. When the behavioral or physiological stressors are frequent/severe, allostatic loading happens. So, both functional and structural changes occur in...
Conclusions: Self-confident approach, social support-seeking approach, and level of psychological well-being predict psychological resilience in migraine patients. Interventions aiming to increase the level of psychological resilience, which is negatively correlated with depression, are expected to increase the quality of life of patients with...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC2yrStress is a huge factor in migraine.
Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36633219/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: This subgroup analysis in patients with CM/MOH at baseline suggests that eptinezumab treatment is associated with early, sustained, and clinically meaningful improvements in patient-reported outcomes.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC2yrTHis is great to see.